Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

Show other versions (1)

Olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. Long acting injections are important alternatives to oral medications for patients who have difficulty adhering...

Full description

Bibliographic Details
Main Authors: Heidi J. Wehring, Sheryl Thedford, Maju Koola, Deanna L. Kelly
Format: Article
Language:English
Published: SAGE Publishing 2011-01-01
Series:Journal of Central Nervous System Disease
Online Access:https://doi.org/10.4137/JCNSD.S4091
id doaj-c41bf87b6a634a37a1a962bd1ffdc8ad
record_format Article
spelling doaj-c41bf87b6a634a37a1a962bd1ffdc8ad2020-11-25T03:31:08ZengSAGE PublishingJournal of Central Nervous System Disease1179-57352011-01-01310.4137/JCNSD.S4091Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting InjectionHeidi J. Wehring0Sheryl Thedford1Maju Koola2Deanna L. Kelly3 Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA. University of Maryland School of Pharmacy, Baltimore, MD, USA. Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA. Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA.Olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. Long acting injections are important alternatives to oral medications for patients who have difficulty adhering to daily or multiple daily medication administrations, yet may be underutilized or not well understood. Patient perceptions, adherence, and preferences are important issues for health care providers to address when discussing treatment options with their patients. Reviewed here are overall patient and health care provider attitudes and perceptions regarding long acting injections and the details of olanzapine long acting injectable, the newest agent, and how it will fit in the marketplace. In addition, efficacy, safety, dosing and use data regarding this newest long acting agent are reviewed and compared to other available long acting agents.https://doi.org/10.4137/JCNSD.S4091
collection DOAJ
language English
format Article
sources DOAJ
author Heidi J. Wehring
Sheryl Thedford
Maju Koola
Deanna L. Kelly
spellingShingle Heidi J. Wehring
Sheryl Thedford
Maju Koola
Deanna L. Kelly
Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
Journal of Central Nervous System Disease
author_facet Heidi J. Wehring
Sheryl Thedford
Maju Koola
Deanna L. Kelly
author_sort Heidi J. Wehring
title Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
title_short Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
title_full Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
title_fullStr Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
title_full_unstemmed Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
title_sort patient and health care provider perspectives on long acting injectable antipsychotics in schizophrenia and the introduction of olanzapine long-acting injection
publisher SAGE Publishing
series Journal of Central Nervous System Disease
issn 1179-5735
publishDate 2011-01-01
description Olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. Long acting injections are important alternatives to oral medications for patients who have difficulty adhering to daily or multiple daily medication administrations, yet may be underutilized or not well understood. Patient perceptions, adherence, and preferences are important issues for health care providers to address when discussing treatment options with their patients. Reviewed here are overall patient and health care provider attitudes and perceptions regarding long acting injections and the details of olanzapine long acting injectable, the newest agent, and how it will fit in the marketplace. In addition, efficacy, safety, dosing and use data regarding this newest long acting agent are reviewed and compared to other available long acting agents.
url https://doi.org/10.4137/JCNSD.S4091
work_keys_str_mv AT heidijwehring patientandhealthcareproviderperspectivesonlongactinginjectableantipsychoticsinschizophreniaandtheintroductionofolanzapinelongactinginjection
AT sherylthedford patientandhealthcareproviderperspectivesonlongactinginjectableantipsychoticsinschizophreniaandtheintroductionofolanzapinelongactinginjection
AT majukoola patientandhealthcareproviderperspectivesonlongactinginjectableantipsychoticsinschizophreniaandtheintroductionofolanzapinelongactinginjection
AT deannalkelly patientandhealthcareproviderperspectivesonlongactinginjectableantipsychoticsinschizophreniaandtheintroductionofolanzapinelongactinginjection
_version_ 1724573418419912704

Similar Items